Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCS1477 in Advanced Haematological Malignancies
NCT04068597Phase 2Recruiting
- Sponsor
- CellCentric
- Start
- Aug 2019
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of inobrodib in haematological malignancy, acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), multiple myeloma (MM), myelodysplastic syndrome (MDS), sponsored by CellCentric. Started Aug 2019; status: recruiting.
02
Drugs
inobrodib
03
Conditions
haematological malignancyacute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04068597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068597.